Additionally, growing evidence from patients treated with “SMN-replacing” molecules show a residual degree of disease progression and only partially relieves it, suggesting that SMN depletion may not be the only causative mechanism in SMA to act against [54]. Here, SMN1 is linked to proximal spinal muscular atrophy.